Thanks. You also should have included ImmunityBio/Nantkwest's 2nd gen Ad5 replication defective viral vector vaccine. It's a E1, E2b, E3 deleted human adenovirus vector vaccine...so you still have a human Ad5 type, but you bypass the pre-immunity issues associated with 1st gen Ad5. Also, they managed to target the nucleocapsid protein, as well as the spike protein. One of the 14 warp speed companies, but yet to be funded. Also working on capsule dose form.
Thank you for sharing your knowledge with us and bringing us all up to speed, Dr. Offit!
Thanks. You also should have included ImmunityBio/Nantkwest's 2nd gen Ad5 replication defective viral vector vaccine. It's a E1, E2b, E3 deleted human adenovirus vector vaccine...so you still have a human Ad5 type, but you bypass the pre-immunity issues associated with 1st gen Ad5. Also, they managed to target the nucleocapsid protein, as well as the spike protein. One of the 14 warp speed companies, but yet to be funded. Also working on capsule dose form.
T cell immunity seems to be robust in Sars cov 2 and antibodies wane, so the vaccines should be targeting T cells aswell as antibodies